在線研討會｜如何在 The Journal of Virus Eradication 發表文章

歡迎參加 The Journal of Virus Eradication 期刊在線研討會！

本次活動將邀請期刊主編、復旦大學上海市公共衛生臨床中心李鋒教授，分享期刊定位、收稿范圍、審稿流程及高質量投稿建議。愛思唯爾執行出版人也將介紹投稿平臺、開放獲取政策與作者支持資源，幫助研究人員更高效地完成投稿并提升發表成功率。

無論您是作者、審稿人，還是熱情的讀者，都歡迎參加本次研討會！

免費注冊參會

研討會時間：

2026年7月15日

北京時間 19:00-20:00

Dr. Feng Li

Editor in Chief

Journal of Virus Eradication

Professor

Shanghai Public Health Clinical Center, Fudan University

上下滑動查看全部簡介

Dr. Feng Li earned his Master of Science in Molecular Immunology from the Chinese Center for Disease Control and Prevention (CDC) and a Ph.D. in Biotechnology and Pharmaceutical Sciences from the Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS). His postdoctoral training at the University of North Carolina at Chapel Hill, under the mentorship of Professor Lishan Su, honed his expertise in developing cutting-edge HBV mouse models. This rigorous academic foundation solidified his proficiency in molecular virology, with a focus on HBV, and prepared him to bridge basic research and clinical applications in viral infectious diseases.

Dr. Li boasts extensive experience studying diverse viruses, including: Hepatitis viruses (HAV, HBV, HCV, HDV), Respiratory pathogens (SARS-CoV-2, influenza, RSV), Emerging threats (Mpox, HIV, Norovirus). One of his expertise is in generating viral infection mouse models, including immune system humanized mouse models, liver-humanized FAH mouse models, innate immunity deficient and Interferon (IFN) pathway humanized mouse for diverse virus infections.

Currently, Dr. Li serves as Professor and Director of the Scientific Research Center at the Shanghai Public Health Clinical Center, Fudan University. His research integrates medical virology, viral-host interactions, and infection immunology, with a core emphasis on 1) Interferon-mediated antiviral therapies for chronic HBV infections, 2) Interferon-associated mucosal antiviral prophylaxis to enhance immune responses at barrier sites, and 3) Translating bench findings to clinical solutions.

Agnieszka Freda

Executive Publisher

Scientific Reproducibility Lead

Elsevier

上下滑動查看全部簡介

Agnieszka Freda is Executive Publisher and Team Lead at Elsevier STM Journals, based in Amsterdam, where she oversees a portfolio of virology and vaccinology journals and co-leads Elsevier’s workstream on scientific reproducibility and SAGER implementation. She holds a Master of Science in Biotechnology from Lodz University of Technology and has been with Elsevier since 2013. Alongside her publishing role, she is an active contributor to science communication and champions gender-responsive and reproducible research practices across Elsevier's journal portfolio and science at large.

Journal of Virus Eradication是一本專注于病毒根除研究的開放獲取專業期刊，涵蓋所有人類病毒相關研究，包括基礎分子病毒學、臨床病毒學、抗病毒藥物研發與臨床試驗、預防及治療性疫苗、公共衛生政策推廣等。期刊大幅精簡編輯審理流程，加快優質論文刊發速度，助力提升文章學術影響力與讀者覆蓋面。

一、基礎病毒學與臨床病毒學

1.病毒復制機制、病毒核酸修飾、病毒 - 宿主相互作用、病毒固有免疫逃逸策略、不同細胞內病毒復制異質性及組織嗜性。

2.病毒突變、演化與宿主適應規律：包括人類免疫缺陷病毒（HIV）、乙型肝炎病毒（HBV）等毒株突變動力學；流感抗原漂移等新發變異病毒、人畜共患病跨物種溢出機制；臨床耐藥突變株基因型解析。

3.病毒感染快速分子檢測技術，特別是即時檢測技術的開發與應用。

4.病毒致病機制及器官特異性損傷機制、病毒混合感染協同致病效應；病毒感染誘導的免疫應答圖譜、免疫保護作用與免疫持久性。

5.抗病毒治療與預防的臨床試驗，含研究者發起臨床試驗（IIT）、Ⅰ/Ⅱ/Ⅲ 期臨床試驗。

二、疫苗與抗病毒治療藥物

1.靶向病毒入侵 / 膜融合、復制關鍵酶（如聚合酶抑制劑）、病毒釋放環節的治療性抗病毒藥物。

2.廣譜抗病毒抑制劑、靶向宿主因子療法及傳統中藥抗病毒制劑。

3.病毒突變與變異株基因組監測、藥物逃逸演化規律及抗病毒耐藥產生機制。

4.疫苗設計、新型疫苗平臺技術（信使核糖核酸 mRNA、病毒載體等）、佐劑創新、疫苗遞送策略及脂質納米顆粒載體。

5.中和抗體開發與應用探索。

三、公共衛生領域

1.基于循證依據評估疫情防控策略（疫苗公平分配、旅行管控措施有效性等）；全球疫苗可及性難題與本土化生產政策研究。

2.病毒傳播動力學建模及精準防控政策制定。

3.病毒感染相關健康公平差距及社會影響因素分析。

4.消除疫苗猶豫的跨人群干預方案。

5.抗病毒藥物、疫苗和治療方案的儲備體系與應急醫療體系建設。